Session

Covid-19 in IBD (Posters)

SEROLOGIC RESPONSE AND SAFETY AFTER THIRD DOSE OF THE COVID-19 BNT162B2 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
SEROLOGIC RESPONSE AND SAFETY AFTER THIRD DOSE OF THE COVID-19 BNT162B2 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

SERUM PROTEOMICS AND METABOLOMICS STUDY ON SUSCEPTIBILITY TO SARS-COV-2 INFECTION IN IBD PATIENTS
SERUM PROTEOMICS AND METABOLOMICS STUDY ON SUSCEPTIBILITY TO SARS-COV-2 INFECTION IN IBD PATIENTS

EXPLORING THE TRASCRIPTOMIC UNDERPINNING THE EFFECT OF BIOLOGICAL THERAPIES ON SARS-COV-2 SUSCEPTIBILITY IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS
EXPLORING THE TRASCRIPTOMIC UNDERPINNING THE EFFECT OF BIOLOGICAL THERAPIES ON SARS-COV-2 SUSCEPTIBILITY IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS

HUMORAL IMMUNOGENICITY AFTER VACCINATION AGAINST SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE PATIENTS UNDER IMMUNOSUPPRESSIVE THERAPY: SHOULD WE PRIORITIZE AN ADDITIONAL BOOSTER INJECTION?
HUMORAL IMMUNOGENICITY AFTER VACCINATION AGAINST SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE PATIENTS UNDER IMMUNOSUPPRESSIVE THERAPY: SHOULD WE PRIORITIZE AN ADDITIONAL BOOSTER INJECTION?

ANTI-TNF THERAPY IS ASSOCIATED WITH ATTENUATED HUMORAL RESPONSE TO SARS-COV-2 VACCINES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD): A CROSS-SECTIONAL STUDY FROM A PORTUGUESE IBD UNIT
ANTI-TNF THERAPY IS ASSOCIATED WITH ATTENUATED HUMORAL RESPONSE TO SARS-COV-2 VACCINES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD): A CROSS-SECTIONAL STUDY FROM A PORTUGUESE IBD UNIT

THE NATURAL HISTORY OF COVID-19 IN VACCINATED INFLAMMATORY BOWEL DISEASE PATIENTS
THE NATURAL HISTORY OF COVID-19 IN VACCINATED INFLAMMATORY BOWEL DISEASE PATIENTS

IMPACT OF IMMUNOTHERAPIES ON RESPIRATORY TRACT INFECTIONS INCLUDING SARS-COV-2 IN IBD PATIENTS
IMPACT OF IMMUNOTHERAPIES ON RESPIRATORY TRACT INFECTIONS INCLUDING SARS-COV-2 IN IBD PATIENTS

ANALYSIS OF THE SEROLOGIC RESPONSE TO COVID-19 VACCINATION IN PAEDIATRIC INFLAMMATORY BOWEL DISEASE
ANALYSIS OF THE SEROLOGIC RESPONSE TO COVID-19 VACCINATION IN PAEDIATRIC INFLAMMATORY BOWEL DISEASE

IMMUNOSUPPRESSANTS EXERT DIFFERENTIAL EFFECTS AGAINST PAN-CORONAVIRUS INFECTION AND DISTINCT COMBINATORY ANTIVIRAL ACTIVITY WITH MOLNUPIRAVIR AND NIRMATRELVIR
IMMUNOSUPPRESSANTS EXERT DIFFERENTIAL EFFECTS AGAINST PAN-CORONAVIRUS INFECTION AND DISTINCT COMBINATORY ANTIVIRAL ACTIVITY WITH MOLNUPIRAVIR AND NIRMATRELVIR

IMMUNOSUPPRESSANTS EXERT DIFFERENTIAL EFFECTS AGAINST PAN-CORONAVIRUS INFECTION AND DISTINCT COMBINATORY ANTIVIRAL ACTIVITY WITH MOLNUPIRAVIR AND NIRMATRELVIR
IMMUNOSUPPRESSANTS EXERT DIFFERENTIAL EFFECTS AGAINST PAN-CORONAVIRUS INFECTION AND DISTINCT COMBINATORY ANTIVIRAL ACTIVITY WITH MOLNUPIRAVIR AND NIRMATRELVIR

Covid-19 in IBD (Posters)  et al.

ANALYSIS OF THE SEROLOGIC RESPONSE TO COVID-19 VACCINATION IN PAEDIATRIC INFLAMMATORY BOWEL DISEASE
ANALYSIS OF THE SEROLOGIC RESPONSE TO COVID-19 VACCINATION IN PAEDIATRIC INFLAMMATORY BOWEL DISEASE

Covid-19 in IBD (Posters)  et al.

IMPACT OF IMMUNOTHERAPIES ON RESPIRATORY TRACT INFECTIONS INCLUDING SARS-COV-2 IN IBD PATIENTS
IMPACT OF IMMUNOTHERAPIES ON RESPIRATORY TRACT INFECTIONS INCLUDING SARS-COV-2 IN IBD PATIENTS

Covid-19 in IBD (Posters)  et al.

THE NATURAL HISTORY OF COVID-19 IN VACCINATED INFLAMMATORY BOWEL DISEASE PATIENTS
THE NATURAL HISTORY OF COVID-19 IN VACCINATED INFLAMMATORY BOWEL DISEASE PATIENTS

Covid-19 in IBD (Posters)  et al.

ANTI-TNF THERAPY IS ASSOCIATED WITH ATTENUATED HUMORAL RESPONSE TO SARS-COV-2 VACCINES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD): A CROSS-SECTIONAL STUDY FROM A PORTUGUESE IBD UNIT
ANTI-TNF THERAPY IS ASSOCIATED WITH ATTENUATED HUMORAL RESPONSE TO SARS-COV-2 VACCINES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD): A CROSS-SECTIONAL STUDY FROM A PORTUGUESE IBD UNIT

Covid-19 in IBD (Posters)  et al.

HUMORAL IMMUNOGENICITY AFTER VACCINATION AGAINST SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE PATIENTS UNDER IMMUNOSUPPRESSIVE THERAPY: SHOULD WE PRIORITIZE AN ADDITIONAL BOOSTER INJECTION?
HUMORAL IMMUNOGENICITY AFTER VACCINATION AGAINST SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE PATIENTS UNDER IMMUNOSUPPRESSIVE THERAPY: SHOULD WE PRIORITIZE AN ADDITIONAL BOOSTER INJECTION?

Covid-19 in IBD (Posters)  et al.

EXPLORING THE TRASCRIPTOMIC UNDERPINNING THE EFFECT OF BIOLOGICAL THERAPIES ON SARS-COV-2 SUSCEPTIBILITY IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS
EXPLORING THE TRASCRIPTOMIC UNDERPINNING THE EFFECT OF BIOLOGICAL THERAPIES ON SARS-COV-2 SUSCEPTIBILITY IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS

Covid-19 in IBD (Posters)  et al.

SERUM PROTEOMICS AND METABOLOMICS STUDY ON SUSCEPTIBILITY TO SARS-COV-2 INFECTION IN IBD PATIENTS
SERUM PROTEOMICS AND METABOLOMICS STUDY ON SUSCEPTIBILITY TO SARS-COV-2 INFECTION IN IBD PATIENTS

Covid-19 in IBD (Posters)  et al.

SEROLOGIC RESPONSE AND SAFETY AFTER THIRD DOSE OF THE COVID-19 BNT162B2 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
SEROLOGIC RESPONSE AND SAFETY AFTER THIRD DOSE OF THE COVID-19 BNT162B2 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Covid-19 in IBD (Posters)  et al.

Item 1 - 18 / 18
1